Glycine transporters: essential regulators of neurotransmission.

Eulenburg V, Armsen W, Betz H, Gomeza J. Glycine transporters: essential regulators of neurotransmission. Trends Biochem Sci. 2005;30(6):325-33. DOI: 10.1016/j.tibs.2005.04.004. PubMed PMID: 15950877.

Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors.

Duplantier AJ, Becker SL, Bohanon MJ, Borzilleri KA, Chrunyk BA, Downs JT, et al. Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors. J Med Chem. 2009;52(11):3576-85. DOI: 10.1021/jm900128w. PubMed PMID: 19438227.

BDNF in schizophrenia, depression and corresponding animal models.

Angelucci F, Brenè S, Mathé AA. BDNF in schizophrenia, depression and corresponding animal models. Mol Psychiatry. 2005;10(4):345-52. DOI: 10.1038/sj.mp.4001637. PubMed PMID: 15655562.

Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system.

Schatz AR, Lee M, Condie RB, Pulaski JT, Kaminski NE. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol Appl Pharmacol. 1997;142(2):278-87. DOI: 10.1006/taap.1996.8034. PubMed PMID: 9070350.

Cannabinoid receptor type 1 located on presynaptic terminals of principal neurons in the forebrain controls glutamatergic synaptic transmission.

Domenici MR, Azad SC, Marsicano G, Schierloh A, Wotjak CT, Dodt H-U, et al. Cannabinoid receptor type 1 located on presynaptic terminals of principal neurons in the forebrain controls glutamatergic synaptic transmission. J Neurosci. 2006;26(21):5794-9. DOI: 10.1523/JNEUROSCI.0372-06.2006. PubMed PMID: 16723537.

Pharmacological interaction between cannabidiol and delta 9-tetrahydrocannabinol.

Karniol IG, Carlini EA. Pharmacological interaction between cannabidiol and delta 9-tetrahydrocannabinol. Psychopharmacologia. 1973;33(1):53-70. PubMed PMID: 4358666.

Characterization of cytochrome P450 3A inactivation by cannabidiol: possible involvement of cannabidiol-hydroxyquinone as a P450 inactivator.

Bornheim LM, Grillo MP. Characterization of cytochrome P450 3A inactivation by cannabidiol: possible involvement of cannabidiol-hydroxyquinone as a P450 inactivator. Chem Res Toxicol. 1998;11(10):1209-16. DOI: 10.1021/tx9800598. PubMed PMID: 9778318.

Genetic Targeting of the Albumin Locus to Treat Hemophilia.

Davidoff AM, Nathwani AC. Genetic Targeting of the Albumin Locus to Treat Hemophilia. N Engl J Med. 2016;374(13):1288-90. DOI: 10.1056/NEJMcibr1600347. PubMed PMID: 27028920.

Researchers Turn to Canine Clinical Trials to Advance Cancer Therapies.

Jacob JA. Researchers Turn to Canine Clinical Trials to Advance Cancer Therapies. JAMA. 2016;315(15):1550-2. DOI: 10.1001/jama.2016.0082. PubMed PMID: 27027696.

Burning Fat by Bugging the System.

Rosen ED. Burning Fat by Bugging the System. N Engl J Med. 2016;374(9):885-7. DOI: 10.1056/NEJMcibr1515457. PubMed PMID: 26962910.